What it's for (Indications)
- Phloroglucinol + trimethylphloroglucinol is indicated for the symptomatic treatment of spasmodic pain in various organ systems.
- This includes, but is not limited to, functional digestive disorders characterized by visceral spasms, such as irritable bowel syndrome, biliary colic, and spastic forms of cholecystitis.
- Furthermore, it is prescribed for spasmodic and painful manifestations of the urinary tract, including renal colic, bladder spasms, and dysuria.
- In gynecology, its use extends to alleviating painful uterine contractions, dysmenorrhea, and spasms associated with obstetrical procedures.
- The primary goal of therapy is to relax smooth muscle and provide relief from acute or chronic spasmodic conditions affecting the gastrointestinal, biliary, urinary, and female reproductive systems, thereby improving patient comfort and quality of life.
- This non-atropinic antispasmodic combination acts directly on smooth muscle fibers, offering effective relief from painful cramps without causing systemic anticholinergic side effects commonly associated with other antispasmodic agents.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of phloroglucinol + trimethylphloroglucinol varies based on the formulation (oral tablets, rectal suppositories, or injectable solution), the severity and acuteness of symptoms, and individual patient response. For oral administration, a typical adult dose usually involves taking one to two tablets (e.g., 80 mg phloroglucinol + 80 mg trimethylphloroglucinol per tablet) two to three times daily as needed, with doses generally separated by at least two hours to maintain therapeutic efficacy. Rectal suppositories are typically administered at similar frequencies. For acute, severe spasmodic pain, particularly in an urgent care setting or during invasive medical procedures, the injectable form (intravenous or intramuscular) may be preferred. An initial intravenous dose typically ranges from 40 mg to 80 mg of phloroglucinol equivalent, which can be repeated if necessary, but should not exceed a maximum daily dose, often around 240 mg to 320 mg total phloroglucinol equivalent, as specified in the product's official prescribing information. Pediatric dosing must be carefully adjusted based on age, weight, and clinical condition under strict medical supervision. It is crucial to always adhere to the specific instructions provided by a healthcare professional or the comprehensive product labeling to ensure safe and effective use, and self-medication without professional advice is strongly discouraged to prevent potential adverse outcomes. |
Safety & Warnings
Common Side Effects
- While generally considered well-tolerated, phloroglucinol + trimethylphloroglucinol can elicit side effects, although these are typically mild, transient, and infrequent.
- The most commonly reported adverse reactions are cutaneous manifestations of hypersensitivity, which may include skin rash, pruritus (itching), and urticaria (hives).
- In rare but more serious instances, severe allergic reactions such as angioedema (swelling beneath the skin), anaphylactic shock (a life-threatening systemic allergic reaction), and fixed drug eruption have been documented, particularly following intravenous administration.
- Other less frequent side effects might encompass general discomforts such as dizziness, headache, nausea, and dyspepsia (indigestion), although a direct causal link to the musculotropic action of the drug is not always established, and these may sometimes be related to individual patient sensitivities or pre-existing conditions.
- Notably, due to its non-atropinic pharmacological profile, this medication does not typically induce classical anticholinergic side effects like dry mouth, blurred vision, constipation, or urinary retention, which differentiates it from other classes of antispasmodic agents.
- Patients should be advised to promptly report any unusual, severe, or persistent symptoms to their prescribing healthcare provider.
- Immediate medical attention is imperative for any signs suggestive of a severe allergic reaction, including difficulty breathing, significant swelling of the face or throat, or a widespread, rapidly progressing rash, as these conditions can be life-threatening and require emergency intervention.
Serious Warnings
- Black Box Warning: NO BLACK BOX WARNING: Phloroglucinol + trimethylphloroglucinol does not currently carry a specific Black Box Warning from the U.S. Food and Drug Administration (FDA) or equivalent national regulatory bodies in most major jurisdictions. Black Box Warnings are typically reserved for drugs with serious, life-threatening adverse effects that necessitate prominent disclosure to prescribers and patients. However, it is crucial for healthcare professionals and patients to be aware that severe hypersensitivity reactions, including but not limited to anaphylactic shock, angioedema, and other systemic allergic responses, have been reported in rare instances, particularly following the intravenous administration of this medication. While not categorized as a formal Black Box Warning, these serious adverse events underscore the critical importance of vigilant patient monitoring during and immediately after administration, especially for the injectable formulation. Healthcare facilities and personnel administering this drug should be fully prepared to manage acute allergic reactions, with readily available emergency equipment and medications such as epinephrine, antihistamines, and corticosteroids. Patients with a known history of severe allergies or previous adverse reactions to similar compounds should be treated with extreme caution, and the overall benefit-risk profile should be meticulously assessed before drug administration. Any emergent signs of an allergic reaction, such as sudden difficulty breathing, significant swelling of the face or throat, a rapidly spreading severe rash, or a sudden and pronounced drop in blood pressure, demand immediate medical attention. This detailed safety information serves as a vital precaution for all involved in the prescribing and use of this medication, highlighting potential serious risks even in the absence of a formal boxed warning.
- Patients with a known history of hypersensitivity or allergic reactions to phloroglucinol, trimethylphloroglucinol, or any excipients present in the specific pharmaceutical formulation are strictly advised against using this medication.
- Caution is particularly warranted during the administration of the injectable form, especially via the intravenous route, due to the rare but documented potential for severe hypersensitivity reactions, including anaphylactic shock; therefore, appropriate resuscitative measures and emergency equipment must be immediately available.
- It is crucial to understand that this medication provides symptomatic relief and does not address the underlying cause of spasmodic pain; thus, a thorough diagnostic evaluation is essential to exclude serious medical conditions that necessitate specific treatments.
- This agent should not be employed in circumstances involving mechanical obstruction of the digestive tract (e.
- g.
- , pyloric stenosis, intestinal obstruction) or the urinary tract (e.
- g.
- , prostatic hypertrophy with urinary retention, complete ureteral blockage), nor in cases of paralytic ileus, as its antispasmodic action could potentially mask a worsening clinical picture or impede timely diagnosis and appropriate surgical or medical intervention.
- While significant drug interactions are not commonly reported, patients should comprehensively inform their physician about all concomitant medications, including prescription drugs, over-the-counter preparations, and herbal supplements, to preempt potential unforeseen effects.
- Pregnant or breastfeeding women should only use this medication if it is unequivocally necessary and after a meticulous risk-benefit assessment conducted by a qualified healthcare professional, given the limited data on its safety in these specific populations.
- Elderly patients and those with severe hepatic or renal impairment should be treated with prudence, although specific dose adjustments are not universally mandated without more explicit guidelines.
How it Works (Mechanism of Action)
Phloroglucinol and trimethylphloroglucinol exert their primary therapeutic effects through a direct musculotropic antispasmodic action on the smooth muscle cells of various organ systems, including the gastrointestinal, biliary, urinary, and uterine tracts. Their mechanism of action is distinct from that of anticholinergic antispasmodics, as they do not antagonize muscarinic receptors. Instead, the spasmolytic effect is believed to stem from their ability to directly influence intracellular calcium levels and second messenger pathways within the smooth muscle cells. Phloroglucinol is thought to inhibit phosphodiesterase, an enzyme responsible for breaking down cyclic nucleotides. This inhibition leads to an increase in intracellular concentrations of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). Elevated levels of cAMP and cGMP activate protein kinases, which subsequently phosphorylate various proteins involved in the regulation of calcium within the smooth muscle cell. This cascade ultimately results in a decrease in free intracellular calcium concentrations, leading to the relaxation of smooth muscle fibers. This direct action alleviates spasms and associated pain without affecting normal physiological peristalsis or inducing systemic anticholinergic side effects such as dry mouth, blurred vision, or urinary retention. The combination with trimethylphloroglucinol is designed to enhance and potentially prolong this spasmolytic effect, offering a more potent and sustained relief from acute spasmodic episodes.